DrKatyMoore
@DrKatyMoore
Deputy Director, Stephenson Cancer Center, FASCO, ASCO BOD. Gynecologic Oncologist focused on drug development and cancer prevention. Opinions here are my own
I am so excited to be co-chairing with you @PTarantinoMD! The faculty traveling to DC to talk about ADCs in solid tumors is AMAZING - we are talking about medications, sequencing, combinations, side effects and what our patients really think of these "magic bullets" @itsnot_pink…
Incredibly excited to chair with @DrKatyMoore the @NRGonc Summer Symposium 2025, fully dedicated to ADCs! All star lineup, with top experts in the development of ADCs across oncology fields (+ super advocate @itsnot_pink) 🗓️ July 24 📍Washington DC 👉 nrgoncology.org/Summer2025Mtg/…
@itsnot_pink = Super advocate, indeed‼️Thanks for including the patient perspective! #bcsm
I’ve been at @NRGonc 2025 this week. So motivating to be around clinical and translational experts and patient advocates all working toward improved outcomes and understanding through CTEP trials. But I also miss my dogs…..
I felt surrounded by brilliant, innovative, patient centered colleagues today. Thank you all for coming to DC
Incredibly proud and grateful for the success of this @NRGonc ADC Symposium in DC! Packed room, outstanding talks from all faculty, and plenty of food for thought to push forward the field of ADC across oncology fields.
Outstanding presentation at @NRGonc summer symposium on ADCs by @StephensonCC’s own @thenasheffect
What “fancy” ADCs are in the pipeline? @thenasheffect reviews the rapidly evolving field of ISACs, DACs, bsADCs and further innovative ways of utilizing the ADC paradigm to selectively deliver anticancer molecules to tumors. Many bumps along the way, a lot of hopes for the future
Excited to be part of the line up! Lots of novel upcoming mechanisms to discuss in the ADC evolving landscape 😊. @DrKatyMoore @PTarantinoMD
Kicking off in <24h, the @NRGonc Summer Symposium on ADCs promises to be epic! With over 230 registered attendees and a world class faculty, it will allow to review the terrific evolutions of this drug class across oncology fields. Still time to register! nrgoncology.org/Summer2025Mtg/…
Boosting this awesome program- young faculty interested in drug development / reg landscape please consider applying aacr.org/professionals/…
Dr Rachel Grisham is an international expert on (many things) low grade serous ovarian cancer and with @BanerjeeSusana has les development of avutometinib and defactinib as the first FDA approval just for LGSOC! Excited to hear her @ovarcome chat.
All things LGSOC next on #OC360LIVE with Dr. Rachel Grisham! July 31, 10:00 AM CST Join via Zoom: us02web.zoom.us/meeting/regist… Have a question you would like to submit? Email us at [email protected] by July 29 or you can Ask The Expert Live. Learn. Ask. Share. Be Empowered!💪
Congratulations to all our new FASCO members! Your service to ASCO supports education, research and patient centered advocacy that has global impact! Well done (but we are not done…..)
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu
Wow- @DrRanaMcKay congratulations - so well deserved
Congratulations to @DrRanaMcKay for receiving the #KCRS25 Catalyst Award! 👏 A true leader, collaborator, and innovator in kidney cancer research. Well deserved! @kidneycan @OncoAlert @DrChoueiri @HHammersMD @montypal @NazliDizman @yekeduz_emre @asco @MikeSerzanMD @arihakimi…
Super proud of my friend and colleague Dr. Jennifer Holter-Chakrabarty, @StephensonCC and @OUCollegeofMed for this important work covering COVID19 and cancer. Relevant today. This took a village to get open at our site and we were so proud to have open and offer to our…
This is an important paper for our patients with gynecologic clear cell. The question is- how would ipi/nivo perform vs SOC (and what is even SOC for OCCC?) and is this enough to get NCCN? I had to battle insurance denials and get free meds for my last patient which took too…
Most viewed this week from @JAMAOnc: Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival. ja.ma/45Zg2mu
Avutometinib and defactinib in low grade ovarian cancer - FDA accelerated approval for KRAS altered tumors and ongoing RAMP 301 will answer efficacy question for KRASwt. This is the first approval in LGS and the first big advance for our patients. Understanding toxicity…
So proud of @thenasheffect and @StephensonCC - doing amazing work
We're thrilled to announce that Abdul Rafeh Naqash, MD, has been awarded a 2025 Conquer Cancer Career Development Award (CDA) by the American Society of Clinical Oncology @ASCO Foundation. @OUHealth Read the full story here: ouhsc.edu/news/details/o…
Wow! Amazing @DrChoueiri so well deserved
Congrats @DrChoueiri!
Honored to be included @Larvol thank you
Recognizing the Top Women Oncologists from @ASCO 2025 at Times Square. This list is based on the most views on X during #ASCO25. @GillSharlene | @Dr_Oncologista | @DrKatyMoore | @DrSGraff | @nataliagandur | @CharuAggarwalMD | @Dr_RShatsky | @DrKarineTawagi | @TiansterZhang |…
State of the Art: Therapies Now and Around the Corner for Gynecologic Cancers | American Society of Clinical Oncology Educational Book ascopubs-org.webproxy2.ouhsc.edu/doi/full/10.12… So proud of this effort with the amazing Drs. Ketta Lorusso and Joyce Liu @ketta_lorusso Thanks #ASCO25 for inviting…
Thank you @AACRPres ! Agree and ready to support
The AACR stands with the scientific community—especially the early-career investigators for whom this situation is particularly devastating. We ask Congress to eliminate these disruptions to ensure that the next generation of cancer scientists will sustain progress for patients.
My career in clinical trials started and continues in the NCTN and now ETCTN. Nicely done
Link: academic.oup.com/jnci/advance-a…